7-Chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione | 46256-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7-Chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione
• 英文别名: 7-chloro-1,3-dimethylpurine-2,6-dione
• CAS: 46256-47-7
• 化学式: C₇H₇ClN₄O₂
• 分子量: 214.61
• InChiKey: JKKPTDAALYJDSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20180339990A1

  公开（公告）日：2018-11-29

  The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W 1 , R 1 and A 1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

  本发明涉及具有公式I的糖苷酸前药化合物的Janus激酶（JAK）抑制剂：其中W1、R1和A1如所定义。本发明还涉及包含这些化合物的药物组合物；使用这些化合物治疗胃肠炎性疾病的方法；以及制备这些化合物的过程和中间体。
• [EN] GLUCURONIDE PRODRUGS OF TOFACITINIB<br/>[FR] PROMÉDICAMENTS À BASE DE GLUCURONIDE DE TOFACITINIB
  申请人：THERAVANCE BIOPHARMA R&D IP LLC

  公开号：WO2018165250A1

  公开（公告）日：2018-09-13

  The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I): (Formula (I)) where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.

  这项发明涉及具有式(I)的Janus激酶（JAK）抑制剂托法替尼的葡萄糖醛酸酯前药化合物：（式(I)）其中A1和R1如所定义。该发明还涉及包含这种化合物的药物组合物；使用这种化合物治疗胃肠道炎症性疾病的方法；以及制备这种化合物的过程和中间体。
• METHODS FOR TREATING NEUROGENIC ORTHOSTATIC HYPOTENSION
  申请人：Theravance Biopharma R&D IP, LLC

  公开号：US20180055831A1

  公开（公告）日：2018-03-01

  The invention relates to methods for treating neurogenic orthostatic hypotension and symptoms thereof using 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine or a pharmaceutically-acceptable salt thereof.

  该发明涉及使用4-[2-(2,4,6-三氟苯氧甲基)苯基]哌啶或其药用盐来治疗神经源性直立性低血压及其症状的方法。
• HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF
  申请人：Chen Ing-Jun

  公开号：US20110118464A1

  公开（公告）日：2011-05-19

  The halogenated xanthine derivatives and the precursors thereof for anti-cancer and anti-metastasis activity and the preparation method thereof are provided. The halogenated xanthine derivatives can further be radio-labeled with the radioactive halide group. The growth of human prostate carcinoma, tongue squamous cell carcinoma, colon adenocarcinoma and lung carcinoma can be inhibited and arrested in G 0 /G 1 phase by KMUP-2Cl (7-[2-[4-(chlorophenyl)-piperazinyl]ethyl]-1,3-dimethyl-8-chloroxanthine). In addition, the growth of human prostate carcinoma LNCaP can be inhibited by KMUP-1 (7-[2-[4-(2-chlorobenzene)-piperazinyl]-ethyl]-1,3-dimethyl-xanthine), and the LNCaP prostate cancer xenograft growth in nude mice is effectively inhibited by the intraperitoneal injection and per oral administration of KMUP-1.

  提供了用于抗癌和抗转移活性的卤代黄嘌呤衍生物及其前体，以及其制备方法。这些卤代黄嘌呤衍生物可以进一步与放射性卤素基团进行标记。通过KMUP-2Cl（7-[2-[4-(氯苯基)-哌嗪基]乙基]-1,3-二甲基-8-氯黄嘌呤），可以抑制和阻断人类前列腺癌、舌鳞状细胞癌、结肠腺癌和肺癌在G0/G1期的生长。此外，KMUP-1（7-[2-[4-(2-氯苯基)-哌嗪基]-乙基]-1,3-二甲基-黄嘌呤）可以抑制人类前列腺癌LNCaP的生长，通过腹腔注射和口服给药KMUP-1可以有效抑制裸鼠体内LNCaP前列腺癌异种移植瘤的生长。
• Smooth muscle spasmolytic agents
  申请人：——

  公开号：US20040248987A1

  公开（公告）日：2004-12-09

  The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, and other smooth muscle contractility conditions. More particularly, the present invention relates to certain metabolically stabilized secondary amines having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects.

  本发明涉及平滑肌松弛剂，含有它们的制药组合物及使用这些化合物和组合物治疗尿失禁和其他平滑肌收缩症状的方法。更具体地说，本发明涉及某些代谢稳定的次级胺，具有平滑肌松弛作用，同时在哺乳动物使用时避免了不良的副作用，如突出的抗胆碱能、心律不齐和心脏抑制作用。